Countervail Corporation


Countervail holds initial pre-IND meeting with Neurology Division of the FDA for guidance on development of a neuroprotectant against sub-lethal nerve agent exposure.

Feedback from the FDA meeting emphasized the criteria involved in developing galantamine as a neuroprotectant against nerve agent exposure. Among other aspects, FDA guidance supported the use of the “Animal Rule” as the appropriate regulatory path.